AU2007333147B2 - Oligonucleotides containing high concentrations of guanine monomers - Google Patents

Oligonucleotides containing high concentrations of guanine monomers Download PDF

Info

Publication number
AU2007333147B2
AU2007333147B2 AU2007333147A AU2007333147A AU2007333147B2 AU 2007333147 B2 AU2007333147 B2 AU 2007333147B2 AU 2007333147 A AU2007333147 A AU 2007333147A AU 2007333147 A AU2007333147 A AU 2007333147A AU 2007333147 B2 AU2007333147 B2 AU 2007333147B2
Authority
AU
Australia
Prior art keywords
oligonucleotide
solvent
seq
coupling
nucleoside
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2007333147A
Other languages
English (en)
Other versions
AU2007333147A1 (en
Inventor
Brian Stephen Sproat
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kuros US LLC
Original Assignee
Kuros US LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kuros US LLC filed Critical Kuros US LLC
Publication of AU2007333147A1 publication Critical patent/AU2007333147A1/en
Assigned to CYTOS BIOTECHNOLOGY AG reassignment CYTOS BIOTECHNOLOGY AG Request for Assignment Assignors: INTEGRATED DNA TECHNOLOGIES, INC.
Priority to AU2013204442A priority Critical patent/AU2013204442A1/en
Application granted granted Critical
Publication of AU2007333147B2 publication Critical patent/AU2007333147B2/en
Assigned to KUROS BIOSCIENCES AG reassignment KUROS BIOSCIENCES AG Request to Amend Deed and Register Assignors: CYTOS BIOTECHNOLOGY AG
Assigned to KUROS US LLC reassignment KUROS US LLC Request for Assignment Assignors: KUROS BIOSCIENCES AG
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00—Processes for the preparation of sugar derivatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00—Processes for the preparation of sugar derivatives
    • C07H1/06—Separation; Purification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/02—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2007333147A 2006-12-12 2007-12-12 Oligonucleotides containing high concentrations of guanine monomers Active AU2007333147B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2013204442A AU2013204442A1 (en) 2006-12-12 2013-04-12 Oligonucleotides Containing High Concentrations of Guanine Monomers

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US86958806P 2006-12-12 2006-12-12
US60/869,588 2006-12-12
PCT/US2007/087183 WO2008073960A2 (en) 2006-12-12 2007-12-12 Oligonucleotides containing high concentrations of guanine monomers

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2013204442A Division AU2013204442A1 (en) 2006-12-12 2013-04-12 Oligonucleotides Containing High Concentrations of Guanine Monomers

Publications (2)

Publication Number Publication Date
AU2007333147A1 AU2007333147A1 (en) 2008-06-19
AU2007333147B2 true AU2007333147B2 (en) 2013-12-19

Family

ID=39456527

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2007333147A Active AU2007333147B2 (en) 2006-12-12 2007-12-12 Oligonucleotides containing high concentrations of guanine monomers

Country Status (7)

Country Link
US (3) US8586728B2 (enExample)
EP (1) EP2125854B1 (enExample)
JP (1) JP5389662B2 (enExample)
CN (1) CN101611048B (enExample)
AU (1) AU2007333147B2 (enExample)
CA (1) CA2671873C (enExample)
WO (1) WO2008073960A2 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102008063490B4 (de) * 2008-12-17 2023-06-15 Merck Patent Gmbh Organische Elektrolumineszenzvorrichtung und Verfahren zum Einstellen des Farbortes einer weiß emittierenden Elektrolumineszenzvorrichtung
WO2012059510A1 (en) 2010-11-02 2012-05-10 Girindus America, Inc. Back pressure control during solid-phase synthesis on polymeric supports
US10040048B1 (en) 2014-09-25 2018-08-07 Synthego Corporation Automated modular system and method for production of biopolymers
CN107428813B (zh) 2014-12-31 2021-08-03 查克美特制药公司 组合肿瘤免疫疗法
JP6891162B2 (ja) * 2015-07-08 2021-06-18 クロス バイオサイエンシズ アーゲー グアニンリッチオリゴヌクレオチド
WO2017173334A1 (en) 2016-04-01 2017-10-05 Checkmate Pharmaceuticals, Inc. Fc receptor-mediated drug delivery
US20190076814A1 (en) 2017-09-11 2019-03-14 Synthego Corporation Biopolymer synthesis system and method
WO2019080704A1 (zh) * 2017-10-25 2019-05-02 深圳华大生命科学研究院 用于核酸合成的微流控芯片
WO2019160866A2 (en) 2018-02-13 2019-08-22 Checkmate Pharmaceuticals, Inc. Compositions and methods for tumor immunotherapy
WO2019197965A1 (en) 2018-04-09 2019-10-17 Checkmate Pharmaceuticals Packaging oligonucleotides into virus-like particles
AU2019340388B2 (en) * 2018-09-11 2026-01-08 Amgen Inc. Purification methods for guanine-rich oligonucleotides
KR102899530B1 (ko) * 2018-10-30 2025-12-15 도레이 카부시키가이샤 핵산의 비특이 결합 억제제, 하이브리디제이션용 시약, 및 핵산의 하이브리디제이션 방법
CN112969527A (zh) * 2018-11-08 2021-06-15 深圳华大生命科学研究院 一种微流控芯片及其制备方法和dna合成方法
WO2021075423A1 (ja) * 2019-10-18 2021-04-22 富士フイルム和光純薬株式会社 ホスホロアミダイト活性化剤
US20230322842A1 (en) * 2020-04-14 2023-10-12 Sumitomo Chemical Company, Limited Composition containing nucleic acid oligomer
CN114425443B (zh) * 2020-10-29 2025-10-31 江苏金斯瑞生物科技有限公司 一种寡核苷酸合成催化剂
GB202114688D0 (en) 2021-10-14 2021-12-01 Exactmer Ltd Solution phase polymer synthesis

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005014110A1 (en) * 2003-07-22 2005-02-17 Cytos Biotechnology Ag Cpg-packaged liposomes
EP1719778A1 (en) * 2004-02-25 2006-11-08 Japan Science and Technology Agency 3'-terminal nucleoside unit containing phosphoramidite

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1984004749A1 (en) 1983-06-01 1984-12-06 Beckman Instruments Inc Novel preparation of nucleoside phosphoramidite intermediates
US20030050263A1 (en) 1994-07-15 2003-03-13 The University Of Iowa Research Foundation Methods and products for treating HIV infection
JP4111403B2 (ja) 1996-10-11 2008-07-02 ザ リージェンツ オブ ザ ユニバーシティー オブ カリフォルニア 免疫刺激ポリヌクレオチド／免疫調節分子複合体
AU7350798A (en) 1997-04-29 1998-11-24 Universiteit Utrecht Corona virus-like particles as tools for vaccination and therapy
CA2288129A1 (en) 1997-05-01 1998-11-12 Chiron Corporation Use of virus-like particles as adjuvants
US6171591B1 (en) 1997-12-08 2001-01-09 Pentamer Pharmaceuticals, Inc. Recombinant nodavirus compositions and methods
US6541438B1 (en) 1998-05-01 2003-04-01 The Procter & Gamble Company Laundry detergent and/or fabric care compositions comprising a modified cellulase
ATE314095T1 (de) 1998-10-21 2006-01-15 Us Health Virusähnliche partikel zur induktion von autoantikörpern
AU768807B2 (en) 1998-11-30 2004-01-08 Cytos Biotechnology Ag Ordered molecular presentation of antigens, method of preparation and use
EP1165773A4 (en) 1999-02-02 2005-01-05 Biocache Pharmaceuticals Inc IMPROVED PLATFORM FOR PRESENTING ANTIGENS
EP2286792A1 (en) 1999-02-26 2011-02-23 Novartis Vaccines and Diagnostics, Inc. Microemulsions with an adsorbent surface, comprising a microdroplet emulsion
KR100863630B1 (ko) 1999-09-25 2008-10-15 유니버시티 오브 아이오와 리써치 파운데이션 면역자극성 핵산
US6949520B1 (en) 1999-09-27 2005-09-27 Coley Pharmaceutical Group, Inc. Methods related to immunostimulatory nucleic acid-induced interferon
IL148844A0 (en) 1999-09-27 2002-09-12 Coley Pharm Group Inc Methods related to immunostimulatory nucleic acid-induced interferon
ATE454901T1 (de) 1999-10-13 2010-01-15 Novartis Vaccines & Diagnostic Verfahren zur erhaltung zellimmuneantworten gegen proteinen
DE60018601T4 (de) 1999-11-24 2008-05-21 Chiron Corp., Emeryville HBV/HCV Virus-ähnliche Partikel
AT409085B (de) 2000-01-28 2002-05-27 Cistem Biotechnologies Gmbh Pharmazeutische zusammensetzung zur immunmodulation und herstellung von vakzinen
EP1261366A4 (en) 2000-02-24 2003-06-18 Univ Leland Stanford Junior ADJUVANT TREATMENT BY IN VIVO ACTIVATION OF DENDRITIC CELLS
AU2002248185A1 (en) 2000-12-14 2002-07-16 Coley Pharmaceutical Group, Inc. Inhibition of angiogenesis by nucleic acids
US20030050268A1 (en) 2001-03-29 2003-03-13 Krieg Arthur M. Immunostimulatory nucleic acid for treatment of non-allergic inflammatory diseases
AU2002347404A1 (en) 2001-09-14 2003-04-01 Cytos Biotechnology Ag In vivo activation of antigen presenting cells for enhancement of immune responses induced by virus like particles
DE60234375D1 (de) 2001-09-14 2009-12-24 Cytos Biotechnology Ag VERPACKUNG VON IMMUNSTIMULIERENDEM CpG IN VIRUSÄHNLICHEN PARTIKELN: HERSTELLUNGSVERFAHREN UND VERWENDUNG
US7524950B2 (en) * 2001-10-31 2009-04-28 Agilent Technologies, Inc. Uses of cationic salts for polynucleotide synthesis
CA2488856A1 (en) 2002-06-20 2003-12-31 Cytos Biotechnology Ag Packaged virus-like particles for use as adjuvants: method of preparation and use
US7537767B2 (en) 2003-03-26 2009-05-26 Cytis Biotechnology Ag Melan-A- carrier conjugates
US20060210588A1 (en) 2003-03-26 2006-09-21 Cytos Biotechnology Ag Hiv-peptide-carrier-conjugates
EP1605973B1 (en) 2003-03-26 2012-09-26 Cytos Biotechnology AG Packaging of immunostimulatory oligonucleotides into virus-like particles: methods of preparation and uses
US20060251623A1 (en) 2003-07-10 2006-11-09 Caytos Biotechnology Ag Packaged virus-like particles
EP1789460B1 (en) * 2004-09-02 2013-01-09 Isis Pharmaceuticals, Inc. Polymeric beads for oligonucleotide synthesis
AU2005286475A1 (en) 2004-09-21 2006-03-30 Cytos Biotechnology Ag Virus-like particles comprising a fusion protein of the coat protein of AP205 and an antigenic polypeptide
JP5484732B2 (ja) 2005-12-14 2014-05-07 サイトス バイオテクノロジー アーゲー 過敏症の治療のための免疫賦活性核酸パッケージ粒子

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005014110A1 (en) * 2003-07-22 2005-02-17 Cytos Biotechnology Ag Cpg-packaged liposomes
EP1719778A1 (en) * 2004-02-25 2006-11-08 Japan Science and Technology Agency 3'-terminal nucleoside unit containing phosphoramidite

Also Published As

Publication number Publication date
US8586728B2 (en) 2013-11-19
EP2125854A2 (en) 2009-12-02
WO2008073960A2 (en) 2008-06-19
CA2671873C (en) 2018-10-09
US20080139797A1 (en) 2008-06-12
AU2007333147A1 (en) 2008-06-19
US20140200338A1 (en) 2014-07-17
JP2010512169A (ja) 2010-04-22
CN101611048A (zh) 2009-12-23
US9914746B2 (en) 2018-03-13
CA2671873A1 (en) 2008-06-19
US20160145293A1 (en) 2016-05-26
JP5389662B2 (ja) 2014-01-15
EP2125854B1 (en) 2016-10-26
WO2008073960A3 (en) 2008-08-07
CN101611048B (zh) 2012-11-07

Similar Documents

Publication Publication Date Title
AU2007333147B2 (en) Oligonucleotides containing high concentrations of guanine monomers
Bonora et al. Large scale, liquid phase synthesis of oligonucleotides by the phosphoramidite approach
JP7377228B2 (ja) グアニンリッチオリゴヌクレオチド
EP2332954A2 (en) Process for the preparation of phosphorothionate oligonucleotides
JP2010248084A (ja) 新規洗浄溶媒を用いるオリゴヌクレオチド合成法
KR20160150051A (ko) Rna 올리고뉴클레오티드 절단 방법
AU2022224306A1 (en) Process for the de-tritylation of oligonucleotides
CN102076703B (zh) 用于制造寡核苷酸的方法
CA2494150A1 (en) Process for separating and deprotecting oligonucleotides
AU2013204442A1 (en) Oligonucleotides Containing High Concentrations of Guanine Monomers
KR20200035267A (ko) 이메텔스타트를 제조하기 위한 향상된 공정
JP2000342265A (ja) オリゴヌクレオチド類の精製方法
WO2023067038A1 (en) Process for oligonucleotide purification
WO2025028656A1 (ja) オリゴヌクレオチドを製造する方法
ES2741025T3 (es) Oligonucleótidos ricos en guanina
EP4041741A1 (en) Method for the production of a catalytically active dna molecule having improved activity and its use in a method of treating asthma

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: CYTOS BIOTECHNOLOGY AG

Free format text: FORMER APPLICANT(S): INTEGRATED DNA TECHNOLOGIES, INC.

FGA Letters patent sealed or granted (standard patent)
HB Alteration of name in register

Owner name: KUROS BIOSCIENCES AG

Free format text: FORMER NAME(S): CYTOS BIOTECHNOLOGY AG

PC Assignment registered

Owner name: KUROS US LLC

Free format text: FORMER OWNER(S): KUROS BIOSCIENCES AG